program
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Expected Milestones Planned Next Steps
EYSUVIS: First and only FDA approved Rx medication specifically indicated for the short-term (up to two weeks) treatment of the signs and symptoms of Dry Eye Disease
  • FDA approved on October 27, 2020
INVELTYS®: First BID corticosteriod indicated for the treatment of post-operative ocular inflammation and pain
  • FDA approved on August 22, 2018
  • US launch in January 2019
KPI-285: rTKI for Retinal Diseases
  • Complete evaluation of our lead compound, KPI-285, for retinal disease
Novel next-generation anti-inflammatories
  • Select lead compounds
program
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Expected Milestones Planned Next Steps
EYSUVIS: First and only FDA approved Rx medication specifically indicated for the short-term (up to two weeks) treatment of the signs and symptoms of Dry Eye Disease
  • FDA approved on October 27, 2020
INVELTYS®: First BID corticosteriod indicated for the treatment of post-operative ocular inflammation and pain
  • FDA approved on August 22, 2018
  • US launch in January 2019
KPI-285: rTKI for Retinal Diseases
  • Complete evaluation of our lead compound, KPI-285, for retinal disease
Novel next-generation anti-inflammatories
  • Select lead compounds

Please review our Privacy Statement. This website uses cookies. By using our website without changing your cookie settings you agree to our use of cookies as described in our Privacy Statement.